High-nuclearity Luminescent Lanthanide Nanocages for Tumor Drug Delivery

There is an unmet need for easy-to-visualize drug carriers that can deliver therapeutic cargoes deep into solid tumors. Herein, we report the preparation of ultrasmall luminescent imine-based lanthanide nanocages, Eu60 and Tb60 (collectively Ln60), designed to encapsulate anticancer chemotherapeutics for tumor therapy. The as-prepared nanocages possess large cavities suitable for the encapsulation of doxorubicin (DOX), yielding DOX@Ln60 nanocages with diameters around 5 nm. DOX@Ln60 are efficiently internalized by breast cancer cells, allowing the cells to be visualized via the intrinsic luminescent property of Ln(III). Once internalized, the acidic intracellular microenvironment promotes imine bond cleavage and the release of the loaded DOX. DOX@Ln60 inhibits DNA replication and triggers tumor cell apoptosis. In a murine triple negative breast cancer (TNBC) model, DOX@Ln60 was found to inhibit tumor growth with negligible side effects on normal tissues. It proved more effective than various controls, including DOX and Ln60. The present nanocages thus point the way to the development of precise nanomedicines for tumor imaging and therapy. Two 60-metal lanthanide nanocages (Ln60, Ln=Eu and Tb) constructed from Schiff base ligands were used as molecular drug delivery agents (DOX@Ln60, DOX=doxorubicin). They provided for effective tumor therapy in a murine model with negligible side effects. Moreover, DOX@Ln60 proved luminescent and efficiently internalized by breast cancer cells, allowing these cells to be readily visualized.+ image